key: cord-0695738-mqozfuk4
authors: Marx, David; Moulin, Bruno; Fafi‐Kremer, Samira; Benotmane, Ilies; Gautier, Gabriela; Perrin, Peggy; Caillard, Sophie
title: First case of COVID‐19 in a kidney transplant recipient treated with belatacept
date: 2020-04-28
journal: Am J Transplant
DOI: 10.1111/ajt.15919
sha: 98fea353e5e96587616426c24be6523a4d43fb59
doc_id: 695738
cord_uid: mqozfuk4

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing public health emergency of international concern. Acute respiratory distress syndrome (ARDS) develops in 3-30% of patients with COVID-19 (1,2), because of direct virus-induced cytopathic effects in the respiratory tract or cytokine storms triggered by the host's immune response. Comorbidities are known to increase the risk of ARDS in SARS-CoV-2-infected patients (1).

To the Editor:

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing public health emergency of international concern. Acute respiratory distress syndrome (ARDS) develops in 3%-30% of patients with COVID-19, 1,2 because of direct virus-induced cytopathic effects in the respiratory tract or cytokine storms triggered by the host's immune response. Comorbidities are known to increase the risk of ARDS in SARS-CoV-2-infected patients. 1 Belatacept-a CTLA4-Ig molecule designed to block the costimulatory B7-CD28 signal needed for activation of effector T cellsis used in kidney transplant recipients (KTRs) to maintain effective long-term immunosuppression while minimizing calcineurin inhibitors (CNIs)-induced nephrotoxicity. However, a recent report has shown that the use of this drug may be associated with severe opportunistic infections. 3 Here, we describe the first case of COVID-19 in a KTR treated with belatacept. The 58-year-old male patient-with a history of 

The data that support the findings of this study are available from the corresponding author upon reasonable request. 

Clinical characteristics of coronavirus disease 2019 in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Opportunistic infections after conversion to belatacept in kidney transplantation

Clinical management of severe acute respiratory infection (SARI) when Covid-19 disease is suspected. Interim guidance

Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment

Clinical features of patients infected with 2019 novel coronavirus in Wuhan